Poseida Therapeutics Inc (PSTX) Market Valuation

The development of somatic gene modification methods by Poseida Therapeutics (PSTX) relies on substantial advances from strategic partners, ensuring financial stability in the absence of mass sales. The company's price evolution, which reached the 0.93 mark, underscores the value of the cell-free PiggyBac delivery system, which allows the firm to exercise pricing power regarding licensing fees. High barriers to entry are maintained by unique patents and stringent FDA oversight of clinical trials.

PSTX (Poseida Therapeutics, Inc.) Market Capitalization history from 07/04/2022 to 01/18/2025

Poseida Corp - analytical breakdowns and key metrics (PSTX)

- market price and analyst price targets:

Price Chart Poseida Therapeutics, Inc.|PSTX - Analyst Median Target

- market capitalization details:

Market Valuation Poseida Corp|PSTX - Aggregate Business Value

- business book valuation details:

Accounting Value per Share Poseida Therapeutics|PSTX - Accounting Capitalization|Market Value to Book Value Ratio poseida.com|PSTX - Company Assets

- debt obligations and liquidity statistics:

- net income and valuation multiples indicators:

PSTX - Company Net Income|Projected Future Earnings Poseida Therapeutics|PSTX - Market Cap to Net Income Ratio|Projected Price to Earnings Poseida|PSTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Poseida Corp|PSTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Poseida Therapeutics|PSTX - Net earnings per share for the last 12 months|Quarterly EPS earnings growth poseida.com|PSTX - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Poseida Therapeutics

Analysis of all company metrics:PSTX (Poseida Therapeutics, Inc.)

Market capitalization reflects the total value of all company shares, determined by multiplying the current share price by the total number of issued shares. This indicator measures market confidence in the business's fundamental assets. By analyzing the company's market value, an investor identifies hidden capital flows and position distribution phases by major players. For Poseida Therapeutics (PSTX), this metric confirms the effective management of its cell therapy platform. A transparent partnership with Roche minimizes risks, stabilizing the market valuation.

Competitor analysis